Evidence map›Paper›PMID 26165383›Full record

ArticleScientific reports2015

Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients.

Michelle A T Hildebrandt, Jack A Roth, Ara A Vaporciyan, Xia Pu, Yuanqing Ye, Arlene M Correa, Jae Y Kim, Stephen G Swisher, Xifeng Wu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  4. Article
  5. Article
  6. Perceived cognitive function for breast cancer survivors: association of genetic and behaviorally related variables for inflammation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Michelle A T HildebrandtDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jack A RothDepartments of Thoracic &Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; and Division of Thoracic Surgery.
Ara A VaporciyanDepartments of Thoracic &Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; and Division of Thoracic Surgery.
Xia PuDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Yuanqing YeDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Arlene M CorreaDepartments of Thoracic &Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; and Division of Thoracic Surgery.
Jae Y Kim1] Departments of Thoracic &Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; and Division of Thoracic Surgery [2] City of Hope National Cancer Center, Durate, CA.
Stephen G SwisherDepartments of Thoracic &Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; and Division of Thoracic Surgery.
Xifeng WuDepartments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USThoracic Surgery Foundation · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
Lung Cancer Chemoradiation: Predictors of SurvivalR01CA111646 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2005 to 2009
$2.9M
NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA111646
6 · The paper itself

Abstract

Post-operative pulmonary complications are the most common morbidity associated with lung resection in non-small cell lung cancer (NSCLC) patients. The TNF/TRAF2/ASK1/p38 kinase pathway is activated by stress stimuli and inflammatory signals. We hypothesized that genetic polymorphisms within this pathway may contribute to risk of complications. In this case-only study, we genotyped 173 germline genetic variants in a discovery population of 264 NSCLC patients who underwent a lobectomy followed by genotyping of the top variants in a replication population of 264 patients. Complications data was obtained from a prospective database at MD Anderson. MAP2K4:rs12452497 was significantly associated with a decreased risk in both phases, resulting in a 40% reduction in the pooled population (95% CI:0.43-0.83, P = 0.0018). In total, seven variants were significant for risk in the pooled analysis. Gene-based analysis supported the involvement of TRAF2, MAP2K4, and MAP3K5 as mediating complications risk and a highly significant trend was identified between the number of risk genotypes and complications risk (P = 1.63 × 10(-8)). An inverse relationship was observed between association with clinical outcomes and complications for two variants. These results implicate the TNF/TRAF2/ASK1/p38 kinase pathway in modulating risk of pulmonary complications following lobectomy and may be useful biomarkers to identify patients at high risk.

Indexed as

AgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleGenetic VariationGenotypeHumansLung NeoplasmsMaleMAP Kinase Kinase Kinase 5MAP Kinase Signaling SystemMiddle AgedPostoperative ComplicationsSignal TransductionTNF Receptor-Associated Factor 2Tumor Necrosis Factor-alphaBiomarkers, TumorMAP3K5 protein, humanMAP Kinase Kinase Kinase 5TNF Receptor-Associated Factor 2Tumor Necrosis Factor-alpha

Identifiers

PMID26165383
PMCPMC4499815
OpenAlexW2401012877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.